04:24 PM EDT, 07/01/2025 (MT Newswires) -- ArriVent BioPharma ( AVBP ) said late Tuesday it plans a $75 million public offering of common shares and pre-funded warrants.

The company said it will offer underwriters a 30-day overallotment option to buy up to an additional 15% of the total offering size.

ArriVent will use the net proceeds to advance activities related to its firmonertinib drug to treat non-squamous non-small cell lung cancer, as well as for general corporate purposes, the company said.

Shares of the company fell 5.7% during after-hours activity.

Price: 19.70, Change: -1.19, Percent Change: -5.70